Aptose Biosciences Inc. reported the first quarter ended March 31, 2026 results: net income $7.6 million, EPS $(2.99) per common share, basic and diluted.
“Net loss per common share, basic and diluted $ (2.99 )”
Aptose Biosciences Inc. — fact timeline
Source-grounded facts extracted from Aptose Biosciences Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Aptose Biosciences Inc. amended credit facility of US$11.1 million with Hanmi Pharmaceuticals Co. Ltd. at six percent (6%) per annum.
“Second Amended and Restated Facility Agreement On February 23, 2026, the Company and Hanmi entered into a US$11.1 million second amended and restated facility agreement with Hanmi (the “ Second A&R Facility Agreement ”).”
Aptose Biosciences Inc. entered into Arrangement Agreement with Hanmi Pharmaceuticals Co. Ltd. and HS North America Ltd. valued at C$2.41 in cash per Common Share (effective 2025-11-18).
“On November 18, 2025, Aptose Biosciences Inc. (the “ Company ”), Hanmi Pharmaceuticals Co. Ltd. (“ Hanmi ”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“ Hanmi Purchaser ” and together with Hanmi, the “ Hanmi Purchasers ”), entered into a definitive arrangement agreement (the “ Arrangement Agreement ”) pursuant to which Hanmi Purchaser will acquire all of the issued and outstanding common shares of the Company”
Aptose Biosciences Inc. engaged Ernst & Young LLP as its auditor.
“on August 1, 2025 the Company announced that the Board of Directors (the “Board”) unanimously approved the selection of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm to serve as the Company’s independent auditor.”
Aptose Biosciences Inc. incurred credit facility of up to US$8.5 million with Hanmi Pharmaceutical Co. Ltd. at six percent (6%) per annum maturing August 31, 2028.
“On June 20, 2025, Aptose Biosciences Inc., as borrower (the “Company”), announced that it had entered into a loan agreement (the “Loan Agreement”) with Hanmi Pharmaceutical Co. Ltd., as lender (“Hanmi”). The Loan Agreement is an uncommitted facility for up to US$8.5 million (the “Facility”)”
Carol Ashe resigned as member of the Board at Aptose Biosciences Inc..
“On June 16, 2025, Carol Ashe notified the Board of Directors (the “Board”) of Aptose Biosciences Inc. (the “Company”) of her intention to resign from her role as a member of the Board effective immediately.”
Aptose Biosciences Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“March 31, 2025, Aptose Biosciences Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not regained compliance with Nasdaq’s minimum stockholder equity requirement in Listing Rule 5550(b)(1), Nasdaq determined to delist the Company’s securities from The Nasdaq Stock Market, effective on April 2, 2025. The Company and board of directors will review all available options, including an appeal to the determination, but will continue to execute its business plan and will seek to list on a U.S. national securities exchange at the ap”
Aptose Biosciences Inc.: Filed articles of amendment under the Canada Business Corporations Act to effect a 1-for-30 reverse stock split of common shares, effective for trading starting February 26, 2025 (effective 2025-02-18).
“The Company’s Board of Directors determined a final ratio of 1-for-30 for the reverse stock split (the “Reverse Stock Split”) and the Company filed articles of amendment under the Canada Business Corporations Act to implement the Reverse Stock Split on February 18, 2025 and announced that the Common Shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market (“Nasdaq”) and the Toronto Stock Exchange (“TSX”) commencing upon market open on February 26, 2025 subject to final confirmation from TSX and Nasdaq.”
Aptose Biosciences Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last thirty (30) consecutive business days, the closing bid price for the Company’s common shares have been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company is required to present its plan of comp”
Aptose Biosciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“”
Aptose Biosciences Inc. reported financial results for first quarter ended March 31, 2024.
“Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024.”
Fletcher Payne was appointed as Senior Vice President, Chief Financial Officer, Chief Business Officer, and Corporate Secretary at Aptose Biosciences Inc..
“The amendment also added the titles of Chief Business Officer and Corporate Secretary to Mr. Payne’s position.”
Rafael Bejar was appointed as Senior Vice President and Chief Medical Officer at Aptose Biosciences Inc..
“The amendment also added the title of Senior Vice President to Mr. Bejar’s position,”
Aptose Biosciences Inc. amended Amended and Restated Warrant to Purchase Common Shares with Hanmi Pharmaceutical Co., Ltd. valued at 2,339,181 warrants at $1.71 per share (effective 2024-04-24).
“On April 24, 2024, Aptose Biosciences Inc. (the “ Company ”) entered into an Amended and Restated Warrant to Purchase Common Shares (the “ Amended Warrant Agreement ”) with Hanmi Pharmaceutical Co., Ltd. (“ Hanmi ”) in order to comply with Listing Rule 5635 of The Nasdaq Stock Market LLC (“ Nasdaq ”).”
Aptose Biosciences Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 2, 2024, Aptose Biosciences Inc. (the “Company”) received a letter (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity of the Company as of December 31, 2023, as reported in the Company’s Annual Report on Form 10-K filed with the SEC on March 26, 2024, was below the minimum requirement of $2,500,000. Notwithstanding the Notification Letter, the Company believes that following the closing of its financings on January 30, 2024 and January 31, 2024”
Aptose Biosciences Inc. received a nasdaq deficiency notice notice regarding other (rules 5635(d)).
“February 29, 2024, Aptose Biosciences Inc. (the “Company”) received a deficiency letter (the “Deficiency Letter”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company’s recent issuance of securities to Hanmi Pharmaceutical Co., Ltd. (the “Hanmi Transaction”) violated 5635(d) because the Company did not obtain shareholder approval prior to such issuance. Nasdaq stated that completion of the Hanmi Transaction involved the issuance of greater than 20% of the issued and outstanding common shares of the Company at a disco”
Aptose Biosciences Inc. amended Amended and Restated Investor's Rights Agreement with Hanmi Pharmaceutical Co., Ltd. (effective 2024-01-25).
“Investor Rights Agreement In connection with the Hanmi Investment, Aptose and Hanmi entered into an Amended and Restated Investor’s Rights Agreement (the “ Investor Rights Agreement ”), which amends and restates the Investor’s Rights Agreement entered by the parties on September 6, 2023.”
Aptose Biosciences Inc. entered into Funding Satisfaction Agreement with Hanmi Pharmaceutical Co., Ltd. (effective 2024-01-25).
“In connection with the completion of the Hanmi Investment, Aptose and Hanmi have entered into an agreement (the “ Funding Satisfaction Agreement ”), dated January 25, 2024, that provides that upon completion of the Hanmi Investment, Hanmi’s obligation to fund the second tranche of its investment pursuant to the subscription agreement entered by Aptose and Hanmi on September 6, 2023, will be deemed to be satisfied.”
Aptose Biosciences Inc. entered into Subscription Agreement with Hanmi Pharmaceutical Co., Ltd. valued at $4.0 million (effective 2024-01-25).
“Subscription Agreement On January 25, 2024, Aptose entered into a subscription agreement (the “ Subscription Agreement ”) with Hanmi Pharmaceutical Co., Ltd., a corporation formed under the laws of the Republic of Korea, pursuant to which Aptose agreed to sell and issue to Hanmi and Hanmi agreed to purchase from Aptose $4.0 million of Aptose’s common shares and warrants to purchase common shares (the “ Hanmi Investment ”).”
Aptose Biosciences Inc. entered into Underwriting Agreement with Newbridge Securities Corporation, as Underwriter valued at approximately $9.0 million in net proceeds from the Offering (effective 2024-01-25).
“Underwriting Agreement On January 25, 2024, Aptose Biosciences Inc. (“ Aptose ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Newbridge Securities Corporation, as Underwriter, pursuant to which Aptose agreed to issue and sell 4,912,280 common shares and 4,912,280 warrants to acquire common shares (the “ Warrants ”) at a combined public offering price of $1.71 per common share and Warrant (the “ Offering ”).”
Aptose Biosciences Inc. entered into Investor Rights Agreement with Hanmi Pharmaceutical Co., Ltd. (effective 2023-09-06).
“In connection with the Hanmi Investment, the Corporation and Hanmi Pharmaceutical entered into an Investor Rights Agreement (the “ Investor Rights Agreement ”).”
Aptose Biosciences Inc. entered into Subscription Agreement with Hanmi Pharmaceutical Co., Ltd. valued at up to $7,000,000 (effective 2023-09-06).
“On September 6, 2023, Aptose Biosciences Inc., a Canadian corporation (the “ Corporation ”), entered into a subscription agreement (the “ Subscription Agreement ”) with Hanmi Pharmaceutical Co., Ltd., a corporation formed under the laws of the Republic of Korea (the “ Hanmi Pharmaceutical ”), pursuant to which the Corporation agreed to sell and issue to Hanmi Pharmaceutical and Hanmi Pharmaceutical agreed to purchase from the Corporation up to $7.0 million of the Corporation’s common shares”
Aptose Biosciences Inc. reported three months ended June 30, 2023 results: net income $(14,129 ) thousand, EPS $(2.27 ) per share.
“Aptose Reports Results for the Second Quarter 2023”
Aptose Biosciences Inc.: Filed articles of amendment to implement a 1-for-15 reverse stock split (effective 2023-06-06).
“The following day, the Company filed articles of amendment under the Canadian Business Corporations Act to implement the Reverse Stock Split.”
Aptose Biosciences Inc. entered into Registration Rights Agreement with Keystone Capital Partners, LLC (effective 2023-05-25).
“Additionally, on May 25, 2023, the Company and Keystone entered into a registration rights agreement (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement with the United States Securities and Exchange Commission (“ SEC ”) covering the resale of Common Shares that are issued to Keystone under the Purchase Agreement.”
Aptose Biosciences Inc. entered into Purchase Agreement with Keystone Capital Partners, LLC valued at $25,000,000 (effective 2023-05-25).
“On May 25, 2023, Aptose Biosciences Inc. (the “ Company ”) and Keystone Capital Partners, LLC (“ Keystone ”), entered into a common share purchase agreement (the “ Purchase Agreement ”), which provides that subject to the terms and conditions set forth therein, the Company may sell to Keystone up to the lesser of (i) $25,000,000 of the Company’s common shares”
Aptose Biosciences Inc. shareholders approved Compensation of Named Executive Officers at the 2023-05-23 meeting.
“Proposal No. 6—Compensation of Named Executive Officers The Corporation’s shareholders voted to approve a non-binding resolution to approve the compensation paid to the Corporation’s named executive officers. Votes For % Votes For Vote Against % Votes Against Abstain Broker Non- Votes 19,458,544 86.50 2,736,388 12.17 298,350 18,604,182”
Aptose Biosciences Inc. shareholders approved Meeting Adjournments at the 2023-05-23 meeting.
“Proposal No. 5—Meeting Adjournments The Corporation’s shareholders voted to approve a resolution permitting one or more adjournments of the meeting, if necessary or appropriate, if a quorum is present, to permit further solicitation of proxies if there are not sufficient votes at the time of the meeting to approve Proposals No. 3 and 4. Votes For % Votes For Vote Against % Votes Against Abstain Broker Non- Votes 33,325,854 81.09 7,660,406 18.64 111,202 2”
Aptose Biosciences Inc. shareholders approved Amendment to Articles to effect a reverse stock split at the 2023-05-23 meeting.
“Proposal No. 4—Amendment to Articles The Corporation’s shareholders voted to approve a special resolution providing for an amendment to the Corporation’s Articles to effect a reverse stock split of the Corporation’s outstanding common shares at a ratio in the range of 1-for-10 to 1-for-20, such amendment to become effective at an exact ratio and a date to be determined by the board of directors of the Corporation if the board of directors considers it to be in the best interests of the Corporation to implement such reverse stock split. Votes For % Votes For Vote Against % Votes Against Abstain Broker Non- Votes 38,399,205 93.44 2,517,058 6.12 181,200 1”
Aptose Biosciences Inc. shareholders approved Amendment to Stock Incentive Plan at the 2023-05-23 meeting.
“Proposal No. 3—Amendment to Stock Incentive Plan The Corporation’s shareholders voted to approve an amendment to the Corporation’s 2021 stock incentive plan to increase the number of common shares reserved for issuance thereunder by 1,027,758 common shares. Votes For % Votes For Vote Against % Votes Against Abstain Broker Non- Votes 13,780,728 61.26 8,645,485 38.44 67,068 18,604,183”
Aptose Biosciences Inc. shareholders approved Appointment of Independent Registered Public Accounting Firm at the 2023-05-23 meeting.
“Proposal No. 2—Appointment of Independent Registered Public Accounting Firm The Corporation’s shareholders voted to approve the appointment of KPMG LLP as the independent registered public accounting firm of the Corporation for the fiscal year ended December 31, 2023. Votes For % Votes For Vote Against % Votes Against Abstain Broker Non- Votes 39,648,697 96.48 1,303,802 3.17 144,965 0”
Aptose Biosciences Inc. shareholders approved Election of Directors at the 2023-05-23 meeting.
“At the meeting, shareholders voted in favor of all items of business, as indicated below: Proposal No. 1—Election of Directors The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2024 Annual General Meeting: Nominee Votes For % Votes For Votes Against %Votes Against Broker Non-Votes Ms. Carol G. Ashe 20,399,773 90.69 2,093,509 9.31 18,604,182 Dr. Denis Burger 20,214,219 89.87 2,279,063 10.13 18,604,182 Dr. Erich Platzer 20,485,136 91.07 2,008,146 8.93 18,604,182 Dr. William G. Rice 14,862,859 66.08 7,630,423 33.92 18,604,182 Dr. Mark D. Vincent 20,417,576 90.77 2,075,706 9.23 18,604,182 Mr. Warren Whitehead 20,482,405 91.06 2,010,877 8.94 18,604,182 Dr. Bernd Seizinger 20,498,713 91.13 1,994,569 8.83 18,604,182”
Aptose Biosciences Inc. reported first quarter ended March 31, 2023 results: net income $ (13,676 ), EPS $ (0.15 ).
“Aptose Biosciences, Inc. Statements of Operations Data (unaudited) ($ in thousands, except per share data) Three months ended March 31, 2023 March 31, 2022 Expenses: Research and development $ 8,811 $ 7,393 General and administrative 5,285 4,107 Operating expenses 14,096 11,500 Other income, net 420 19 Net loss $ (13,676 ) $ (11,481 ) Net Loss per share, Basic and diluted $ (0.15 ) $ (0.12 )”
Aptose Biosciences Inc. reported the year ended December 31, 2022 results: net income $41.8 million, EPS ($0.45 per share).
“The net loss for the year ended December 31, 2022, was $41.8 million ($0.45 per share) compared with $65.4 million ($0.73 per share) for the year ended December 31, 2021.”
Aptose Biosciences Inc. reported the quarter ended December 31, 2022 results: net income $10.0 million, EPS ($0.11 per share).
“The net loss for the quarter ended December 31, 2022, was $10.0 million ($0.11 per share) compared with $24.3 million ($0.27 per share) for the quarter ended December 31, 2021.”
Aptose Biosciences Inc. entered into Equity Distribution Agreement with JonesTrading Institutional Services LLC (effective 2022-12-09).
“On December 9, 2022, Aptose Biosciences Inc. entered into an Equity Distribution Agreement (the “EDA”) with JonesTrading Institutional Services LLC, as agent, (the “Agent”) in connection with the establishment of an “at-the-market” sales facility.”
Aptose Biosciences Inc. terminated Equity Distribution Agreement with Piper Sandler & Co. and Canaccord Genuity LLC valued at up to an aggregate of $75,000,000 (effective 2022-11-18).
“On November 18, 2022, Aptose Biosciences Inc. (the “Company”) delivered written notice to Piper Sandler & Co. and Canaccord Genuity LLC (together, the “Placement Agents”) to terminate that certain Equity Distribution Agreement dated May 5, 2020 by and between the Company and the Placement Agents (the “Equity Distribution Agreement”).”
Aptose Biosciences Inc. reported the nine months ended September 30, 2022 results: revenue $ -, net income $31.8 million, EPS $ (0.34).
“Net loss for the nine-month period ended September 30, 2022 decreased by $9.2 million to $31.8 million, as compared to $41.0 million for the comparable period in 2021.”
Aptose Biosciences Inc. reported the quarter ended September 30, 2022 results: revenue $ -, net income $9.8 million, EPS ($0.11 per share).
“The net loss for the quarter ended September 30, 2022 was $9.8 million ($0.11 per share) compared with $11.3 million ($0.13 per share) for the quarter ended September 30, 2021.”
Dr. Bernd R. Seizinger, M.D., Ph.D. was appointed as Director at Aptose Biosciences Inc..
“On September 13, 2022, Aptose Biosciences Inc. (“we” or the “Company”) appointed Dr. Bernd R. Seizinger, M.D., Ph.D. to its Board of Directors (the “Board”).”
Fletcher Payne was appointed as Senior Vice President and Chief Financial Officer at Aptose Biosciences Inc..
“On June 27, 2022, Aptose Biosciences Inc. (“we” or the “Company”) appointed Mr. Fletcher Payne as its Senior Vice President and Chief Financial Officer.”
Dr. Rice changed role as Chief Accounting Officer at Aptose Biosciences Inc..
“Dr. Rice will serve as Chief Accounting Officer, and with Ms. Janet Clennett, Vice President of Finance, will assume financial responsibilities until a permanent CFO is announced.”
Jotin Marango departed as Senior Vice President, Chief Financial Officer and Chief Business Officer at Aptose Biosciences Inc..
“Aptose also announced on April 07, 2022 that Dr. Jotin Marango, Senior Vice President, Chief Financial Officer and Chief Business Officer, is resigning to pursue another opportunity.”
Philippe Ledru was appointed as Chief Commercial Officer at Aptose Biosciences Inc..
“On April 6, 2022, Aptose Biosciences Inc. appointed Mr. Philippe Ledru as its Chief Commercial Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.